2026 Q2 -tulosraportti
9 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·19 min sittenI also think I am too heavily invested in Novo right now. I have no doubt that the Wegovy pill will be a revival for Novo and a huge success worldwide, but for some reason, that potential cannot be seen in the share price right now, and that surprises me. Thinking of lightening my Novo position a bit relative to the world index to come back to Novo when the train is picking up speed a bit more. Are there others who have the same thoughts. ?
I've definitely also had those thoughts, but I don't want to miss out on the rally! 📈
·57 min sitten · MuokattuWhere will Novo go by year-end......Well, the market probably already prices in Lilly's competition and Novo's declining growth. So far so good... But the market (read; the analysts) seems to be short-sighted (probably have to look out for their own ass) - including young investors at Nordnet :-) Jokes aside... Novo has raised its 2026-guidance and my estimate in DKK at year-end 2026 is: - Bear: 250-290 - Base: 350-380 - Bull: 400-440 Yes, because Novo doesn't necessarily need massive growth to reach 350-400. If EPS stabilizes around 26-28, and the market is again willing to pay P/E 14-15, that gives a price of approx. 365-420. The crucial thing is whether the pill can create growth. But that probably can't surprise anyone. And if you're one of those who daily write curses about the stock price... you must be a trader and by no means an investor. Well, BUT then Berenberg comes and downgrades Novo. I think they just want to draw attention to themselves: - Yes, Lilly is a real threat, but saying they will "win over Novo" is simply not correct. Lilly is a threat, but against what? Lilly won't get 100% of the market...forget it. So besides there being no factual basis for this; it is highly unprofessional to announce it. Novo has announced that the obesity market will not be a winner-takes-all market, and that Wegovy still has about 90 % of the GLP-1 market. They also say that pills could make up to half of the GLP-1 market by 2030. This claim is damn more concrete than "Lilly is a real threat" (haven't gone into details though - if such exist after the previous Berenberg announcement..primary source is missing for me). But anyway, 305 is not critical. - AWS collaboration, is that a threat in the period leading up to year-end? It probably can't make much of an impact anyway, can it? - Awiqli? Probably won't be a stock price catalyst, but, but Novo gets another product here where convenience is important. That surely can't be downgraded.... ask the patients and not the economists. Awiqli is simply a free option. Thanks for that, Novo. - Bloomington is, however, crap. But isn't it really just an operational risk.... don't really know. - The Lilly case? That was in "the old days". Novo simply no longer stands weak on efficacy, as many headlines suggest. Not all analysts have realized this yet. I find it hard to find counterarguments that hold up. In the pill market, Novo is very far ahead, and let's hope that continues.
One gradually thought that everything should be priced in novo, unfortunately one is constantly negatively surprised.
·1 t sitten😂😂😂how many here will admit that they bought the Novo share on the recommendation of Kim, aged 19, and his girlfriend A10A after they proclaimed that it would never go below 300 kr again 🤣🤣🤣
Strongly considered putting the entire inheritance into Novo but you love the kids anyway when it comes down to it!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
9 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·19 min sittenI also think I am too heavily invested in Novo right now. I have no doubt that the Wegovy pill will be a revival for Novo and a huge success worldwide, but for some reason, that potential cannot be seen in the share price right now, and that surprises me. Thinking of lightening my Novo position a bit relative to the world index to come back to Novo when the train is picking up speed a bit more. Are there others who have the same thoughts. ?I've definitely also had those thoughts, but I don't want to miss out on the rally! 📈
- ·57 min sitten · MuokattuWhere will Novo go by year-end......Well, the market probably already prices in Lilly's competition and Novo's declining growth. So far so good... But the market (read; the analysts) seems to be short-sighted (probably have to look out for their own ass) - including young investors at Nordnet :-) Jokes aside... Novo has raised its 2026-guidance and my estimate in DKK at year-end 2026 is: - Bear: 250-290 - Base: 350-380 - Bull: 400-440 Yes, because Novo doesn't necessarily need massive growth to reach 350-400. If EPS stabilizes around 26-28, and the market is again willing to pay P/E 14-15, that gives a price of approx. 365-420. The crucial thing is whether the pill can create growth. But that probably can't surprise anyone. And if you're one of those who daily write curses about the stock price... you must be a trader and by no means an investor. Well, BUT then Berenberg comes and downgrades Novo. I think they just want to draw attention to themselves: - Yes, Lilly is a real threat, but saying they will "win over Novo" is simply not correct. Lilly is a threat, but against what? Lilly won't get 100% of the market...forget it. So besides there being no factual basis for this; it is highly unprofessional to announce it. Novo has announced that the obesity market will not be a winner-takes-all market, and that Wegovy still has about 90 % of the GLP-1 market. They also say that pills could make up to half of the GLP-1 market by 2030. This claim is damn more concrete than "Lilly is a real threat" (haven't gone into details though - if such exist after the previous Berenberg announcement..primary source is missing for me). But anyway, 305 is not critical. - AWS collaboration, is that a threat in the period leading up to year-end? It probably can't make much of an impact anyway, can it? - Awiqli? Probably won't be a stock price catalyst, but, but Novo gets another product here where convenience is important. That surely can't be downgraded.... ask the patients and not the economists. Awiqli is simply a free option. Thanks for that, Novo. - Bloomington is, however, crap. But isn't it really just an operational risk.... don't really know. - The Lilly case? That was in "the old days". Novo simply no longer stands weak on efficacy, as many headlines suggest. Not all analysts have realized this yet. I find it hard to find counterarguments that hold up. In the pill market, Novo is very far ahead, and let's hope that continues.One gradually thought that everything should be priced in novo, unfortunately one is constantly negatively surprised.
- ·1 t sitten😂😂😂how many here will admit that they bought the Novo share on the recommendation of Kim, aged 19, and his girlfriend A10A after they proclaimed that it would never go below 300 kr again 🤣🤣🤣Strongly considered putting the entire inheritance into Novo but you love the kids anyway when it comes down to it!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
9 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·19 min sittenI also think I am too heavily invested in Novo right now. I have no doubt that the Wegovy pill will be a revival for Novo and a huge success worldwide, but for some reason, that potential cannot be seen in the share price right now, and that surprises me. Thinking of lightening my Novo position a bit relative to the world index to come back to Novo when the train is picking up speed a bit more. Are there others who have the same thoughts. ?I've definitely also had those thoughts, but I don't want to miss out on the rally! 📈
- ·57 min sitten · MuokattuWhere will Novo go by year-end......Well, the market probably already prices in Lilly's competition and Novo's declining growth. So far so good... But the market (read; the analysts) seems to be short-sighted (probably have to look out for their own ass) - including young investors at Nordnet :-) Jokes aside... Novo has raised its 2026-guidance and my estimate in DKK at year-end 2026 is: - Bear: 250-290 - Base: 350-380 - Bull: 400-440 Yes, because Novo doesn't necessarily need massive growth to reach 350-400. If EPS stabilizes around 26-28, and the market is again willing to pay P/E 14-15, that gives a price of approx. 365-420. The crucial thing is whether the pill can create growth. But that probably can't surprise anyone. And if you're one of those who daily write curses about the stock price... you must be a trader and by no means an investor. Well, BUT then Berenberg comes and downgrades Novo. I think they just want to draw attention to themselves: - Yes, Lilly is a real threat, but saying they will "win over Novo" is simply not correct. Lilly is a threat, but against what? Lilly won't get 100% of the market...forget it. So besides there being no factual basis for this; it is highly unprofessional to announce it. Novo has announced that the obesity market will not be a winner-takes-all market, and that Wegovy still has about 90 % of the GLP-1 market. They also say that pills could make up to half of the GLP-1 market by 2030. This claim is damn more concrete than "Lilly is a real threat" (haven't gone into details though - if such exist after the previous Berenberg announcement..primary source is missing for me). But anyway, 305 is not critical. - AWS collaboration, is that a threat in the period leading up to year-end? It probably can't make much of an impact anyway, can it? - Awiqli? Probably won't be a stock price catalyst, but, but Novo gets another product here where convenience is important. That surely can't be downgraded.... ask the patients and not the economists. Awiqli is simply a free option. Thanks for that, Novo. - Bloomington is, however, crap. But isn't it really just an operational risk.... don't really know. - The Lilly case? That was in "the old days". Novo simply no longer stands weak on efficacy, as many headlines suggest. Not all analysts have realized this yet. I find it hard to find counterarguments that hold up. In the pill market, Novo is very far ahead, and let's hope that continues.One gradually thought that everything should be priced in novo, unfortunately one is constantly negatively surprised.
- ·1 t sitten😂😂😂how many here will admit that they bought the Novo share on the recommendation of Kim, aged 19, and his girlfriend A10A after they proclaimed that it would never go below 300 kr again 🤣🤣🤣Strongly considered putting the entire inheritance into Novo but you love the kids anyway when it comes down to it!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt